Skip to content

GMP Compliance & Medical Device Registration

1. GMP (Good Manufacturing Practice) Overview

Solarbio applies current Good Manufacturing Practice (cGMP) principles across all in vitro diagnostic (IVD) reagent production lines, in alignment with the 2010 Revised GMP requirements enforced by China's National Medical Products Administration (NMPA, formerly CFDA) and international GMP guidelines (ICH Q7, WHO TRS).

GMP compliance governs the following operational domains:

Domain Key Requirements Solarbio Implementation
Facility & Equipment Cleanroom classification (Grade C/D), HVAC qualification, water purification system ISO 8 cleanroom (Grade D) for IVD filling; WFI-grade water system
Personnel GMP training (initial + annual), hygiene protocols, health monitoring All production staff trained to cGMP standard; annual GMP refresher
Raw Materials Supplier qualification, identity testing, approved supplier list HPLC/NMR/FTIR identity verification on receipt; annual supplier audits
Production Batch records, in-process controls, deviation management, process validation Electronic batch records; validated processes per ICH Q8/Q9/Q10
Quality Control QC laboratory operations, stability testing, retain sample management Dedicated QC lab with HPLC, GC-MS, UV-Vis, plate readers; ICH Q1A stability
Documentation SOPs, specifications, master formulas, batch records, change control Documented QMS per ISO 13485 + GMP documentation hierarchy
Laboratory Controls Method validation, OOS investigation, reference standards, sampling plans USP/EP/JP method validation; 21 CFR 211 OOS procedure
Complaint Handling Complaint classification, investigation, trend analysis, CAPA Digital complaint tracking; monthly trend reports; CAPA within 60 days
Self-Inspection Internal audits, cross-departmental audit teams, audit reports Annual internal GMP audit schedule; audit finding closure within 30 days

1.1 2010 Revised GMP (China)

China's 2010 Revised GMP (implemented fully from 2011–2015) introduced significantly stricter requirements for pharmaceutical and IVD manufacturers, including:

  • Quality Risk Management aligned with ICH Q9
  • Pharmaceutical Quality System (PQS) per ICH Q10
  • Process Validation throughout the product lifecycle (Stage 1: Process Design, Stage 2: Process Qualification, Stage 3: Continued Process Verification)
  • Water System Validation — pharmaceutical-grade purified water and WFI distribution systems
  • Cleanroom Classification — ISO 14644-based classification and monitoring
  • Computerized System Validation for production control and QC data systems
  • Supplier Audit Requirements — mandatory on-site audits for critical raw material suppliers

1.2 ICH Q10 Pharmaceutical Quality System

Solarbio's quality management system follows the ICH Q10 model, structured around four elements:

ICH Q10 Element Solarbio Implementation Key Documentation
Process Performance & Product Quality Monitoring Real-time in-process control at defined checkpoints; annual product quality review In-process logs; Annual Product Quality Review (APQR)
Corrective and Preventive Action (CAPA) System Tiered investigation: Minor → Root cause analysis (RCA); Major → Formal RCA with effectiveness check CAPA form with fishbone diagram; 5-Why analysis
Change Management Classification (minor/major/critical); cross-functional review board Change Control Request (CCR) form; Change Control Board (CCB)
Management Review Quarterly QMS review by senior management; annual quality management review Meeting minutes with action items and KPIs

1.3 GMP Documentation Hierarchy

Solarbio's GMP documentation follows a four-tier pyramid:

Tier 1 — Quality Manual
  └─ Quality policy, scope, organizational structure
Tier 2 — Site Master File (SMF)
  └─ Site description, process overview, facility layout
Tier 3 — Standard Operating Procedures (SOPs)
  └─ Over 200 active SOPs covering all GMP-critical operations
      • Production SOPs (weighing, compounding, filling, labeling)
      • QC SOPs (sampling, testing, equipment operation, method validation)
      • Facility SOPs (cleaning, HVAC operation, water system, pest control)
      • Documentation SOPs (batch record issuance, deviation, change control)
Tier 4 — Records and Forms
  └─ Batch production records, QC test records, equipment logs, training records

All GMP documents are controlled through a document management system with unique document numbers, revision history, approval workflow, and periodic review (minimum every 2 years).

2. Medical Device Classification — China NMPA Regulatory Framework

2.1 Classification System

In China, medical devices are classified under NMPA Order No. 15 (2021 Revision) into three classes based on risk level. Solarbio products relevant to medical device registration fall primarily under Class I and Class II:

Class Risk Level Regulatory Pathway Examples (Solarbio)
Class I Low risk Filing (备案) with municipal NMPA General laboratory reagents, buffer solutions, sample diluents, general staining reagents not intended for diagnostic use
Class II Moderate risk Registration (注册) with provincial NMPA In vitro diagnostic (IVD) reagents for disease screening/diagnosis: ELISA kits for cytokine/hormone quantification, clinical chemistry assays (ALT, AST, creatinine, BUN), PCR-based detection reagents
Class III High risk Registration with national NMPA Not generally applicable to standard Solarbio products; covers implantable devices, life-supporting devices

2.2 Class I Medical Device Filing (备案)

Regulatory basis: NMPA Order No. 19 — Medical Device Registration and Filing Management Measures

Requirements for Class I filing:

Requirement Detail
Filing authority Municipal-level NMPA office (e.g., Beijing Municipal Medical Products Administration)
Required documents Product standard, product test report, instruction manual, risk analysis report
Review timeline 5–10 working days (no technical review required)
Certificate validity No expiration (ongoing validity as long as product and manufacturing conditions remain unchanged)
Post-market obligations Adverse event monitoring, annual product quality summary

Solarbio Class I filing examples: - General laboratory buffer solutions (PBS, TBS, SDS-PAGE running buffer) - Sample preparation reagents (tissue homogenization buffer, cell lysis buffer) - General staining reagents and histological stains (H&E stain components, mounting media)

2.3 Class II Medical Device Registration (注册)

Regulatory basis: NMPA Order No. 19, with additional technical review requirements per NMPA Order No. 5 (IVD Reagent Registration)

Requirements for Class II registration:

Requirement Detail
Registration authority Provincial NMPA office (e.g., Beijing Medical Products Administration)
Technical review body Provincial Medical Device Technical Review Center
Required documents Product registration application, product technical requirements, test report from accredited testing institution, clinical evaluation report (or exemption documentation), quality management system documentation
Technical review timeline 80–120 working days (typical)
Certificate validity 5 years (renewable)
Clinical evaluation Clinical trial exemption available for IVD reagents listed in NMPA Exemption Catalog; otherwise, clinical trial required and exemption catalog for many routine IVD reagents
Post-market obligations Adverse event monitoring, periodic risk assessment, design change reporting

Solarbio Class II registration examples: - Clinical ELISA kits for cytokine quantification (IL-6, TNF-α, IFN-γ) - Clinical chemistry assay kits (ALT, AST, creatinine, BUN for serum/plasma testing) - Detection reagents for infectious disease markers

2.4 Registration Process for Class II IVD Reagents

Stage 1: Preparation
  ├─ Determine product classification (IVD reagent category by intended use)
  ├─ Draft product technical requirements (性能指标)
  └─ Prepare quality management system documentation

Stage 2: Type Testing (型式检验)
  ├─ Submit 3 production lots to NMPA-accredited testing laboratory
  ├─ Electrical safety testing (if instrument-based), performance testing
  └─ Testing timeline: 40–90 working days

Stage 3: Clinical Evaluation (临床评价)
  ├─ Determine clinical evaluation pathway:
  │   ├─ Exemption pathway (product listed in NMPA IVD Exemption Catalog)
  │   └─ Clinical trial pathway (IRB-approved, NMPA-registered)
  └─ Clinical trial timeline: 6–18 months (if required)

Stage 4: Registration Submission
  ├─ Compile registration dossier (eCTD format)
  ├─ Submit to Provincial NMPA technical review center
  └─ Timeline: 80–120 working days for review

Stage 5: Post-Approval
  ├─ Obtain Medical Device Registration Certificate (有效期5年)
  ├─ Obtain Medical Device Production License (生产许可证)
  └─ Post-market surveillance and renewal application within 6 months before expiry

2.5 Medical Device Production License (生产许可证)

Manufacturers of Class II medical devices must obtain a Medical Device Production License from the provincial NMPA:

Requirement Detail
Issuing authority Provincial NMPA
Prerequisite Valid Medical Device Registration Certificate (for at least one product)
QMS requirement On-site inspection per NMPA Medical Device QMS requirements (MMPA Order No. 66)
License validity 5 years (renewable)
Scope Must cover the specific product categories registered
Post-approval changes Address change, production scope change, legal representative change must be reported

3. Comparison: GMP vs ISO 13485 vs ISO 9001

Aspect ISO 9001:2015 ISO 13485:2016 GMP (2010 Revised, China)
Scope General QMS Medical device QMS Pharmaceutical & IVD manufacturing
Regulatory alignment None EU MDR, IVDR, FDA QSR, JPAL, China NMPA China NMPA-specific
Risk management Not required ISO 14971 mandatory ICH Q9 risk management
Process validation Not required Required (sterilization, software) Required (all critical processes)
Cleanroom classification Not specified Not specified ISO 14644 Grade C/D
Water quality Not specified Not specified Purified water / WFI per Chinese Pharmacopoeia
Retention samples Not required Not required Required (at least 1× full testing quantity)
Batch release Not required Not required QC release + authorized person release
Self-inspection frequency As scheduled As scheduled At least annually (GMP-specific)
Certification body Third-party (e.g., SGS, TÜV) Third-party (notified body) NMPA on-site inspection

Integrated Management System

Solarbio operates an Integrated Management System (IMS) that harmonizes ISO 9001, ISO 13485, ISO 14001, ISO 45001, and GMP requirements into a unified policy framework. The IMS approach reduces duplication (single SOP for document control serving all standards) while meeting the highest applicable requirement from each standard.

4. Quality Risk Management per ICH Q9 / ISO 14971

Solarbio applies structured risk management across all GMP-critical and medical device processes:

Risk Management Step Method Example
Hazard identification Process FMEA (pFMEA) Contamination risk during aseptic filling
Risk analysis Severity × Occurrence × Detection (RPN) Severity 9 (patient harm) × O 3 × D 2 = RPN 54
Risk evaluation Acceptance criteria matrix RPN > 50 requires mandatory risk control
Risk control Engineering + procedural controls HEPA filtration (engineering) + media fill validation (procedural)
Risk review Annual product risk review Review of all risk controls, CAPA trends, complaint data
Risk communication Cross-functional risk review board Production, QC, QA, and R&D participation

5. Regulatory Compliance Documentation

Document Type Applicable To Retention Period Examples
Medical Device Registration Certificate (医疗器械注册证) Class II products 5 years (renewable) ELISA kit registration, clinical chemistry kit registration
Medical Device Production License (医疗器械生产许可证) Class II manufacturing site 5 years (renewable) Beijing production facility license
Class I Filing Certificate (医疗器械备案凭证) Class I products Ongoing Buffer solution filing
GMP Certificate (GMP证书) IVD reagents (China NMPA inspection) Valid until next inspection NMPA GMP inspection report
Type Testing Report (型式检验报告) Class II registration Per registration submission NMPA-accredited lab test reports
Clinical Evaluation Report (临床评价报告) Class II registration (examption pathway) Per registration submission Literature-based clinical evaluation

6. Cross-References

For regulatory documentation and compliance inquiries: solarbio.store